Resources

Novel Coronavirus (COVID-19) Vaccine Development – Wave 2

Given the recent uptick in COVID-19 cases in the US, many InCrowd panelists have been reporting that they do not expect things to return to normal until a vaccine is developed and disseminated. In order to deepen our understanding of the COVID-19 vaccine landscape, we surveyed infectious disease specialists across the country to get their perception and predictions on the efficacy, impact, and competitive landscape of COVID-19 vaccines.*

* Please note, views in this survey reflect opinions only as reported by responding physicians.

Methodology:

  • Method:
    • 12-Minute MicroSurvey via InCrowd
  • Crowds:
    • Infectious disease doctors
  • Sample Size:
    • n = 100
      • Community Hospital, Academic Hospital, Office-based
  • Fielding Period:
    • October 22nd – 26th

InCrowd’s other COVID-19 Tracking Reports:

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

ASH 2022 Real-Time Round-Up

ASH 2022 Real-Time Round-Up

The 2022 Annual Meeting of the American Society of Hematology (ASH) took place in person from December 10th to the 13th. InCrowd wanted to learn from those Hematologists and Hematology-Oncologists who attended these two objectives: Explore which condition had the most...

read more
RSV Tracker: Wave 3

RSV Tracker: Wave 3

Due to the surge in US respiratory syncytial virus (RSV) cases amongchildren and adults as reported in the news, InCrowd was interested inlearning more from Emergency Room physicians to understand thefollowing: • Growth in RSV cases over time• Severity-level changes...

read more